UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | May 22, 2007 |
Impax Laboratories, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 000-27354 | 65-0403311 |
| _____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 30831 Huntwood Avenue, Hayward, California | 94544 | |
| _________________________________ (Address of principal executive offices) | ___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 510-476-2000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
Press Release
On May 22, 2007, the registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1, announcing that it had filed a petition with the Securities and Exchange Commission asking the Commission to review the April 30, 2007 decision of its Administrative Law Judge that would revoke the registration under the Securities Exchange Act of the registrant's common stock.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 - Press release dated May 22, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Impax Laboratories, Inc. | ||||
| May 22, 2007 | By: | /s/ Arthur A. Koch, Jr. | ||
| Name: Arthur A. Koch, Jr. | ||||
| Title: Chief Financial Officer | ||||
Exhibit Index
| Exhibit No. | Description | |
99.1 | Press Release |
